S3:E3 – Non-Small Cell Lung Cancer Morning Commute: What’s on the Horizon? Podcast Por  arte de portada

S3:E3 – Non-Small Cell Lung Cancer Morning Commute: What’s on the Horizon?

S3:E3 – Non-Small Cell Lung Cancer Morning Commute: What’s on the Horizon?

Escúchala gratis

Ver detalles del espectáculo
OFERTA POR TIEMPO LIMITADO. Obtén 3 meses por US$0.99 al mes. Obtén esta oferta.

Visit MorningCommutePodcast.com/NSCLC3 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit. In this episode, our experts will discuss New therapies in the pipeline as well as immunotherapy combinations. At the time this podcast was recorded, cemiplimab was pending approval.

Todavía no hay opiniones